Clinical trials exploring prostate specific membrane antigen (PSMA) and delta-like protein 3 (DLL3) targeted therapies (e.g., Lu177-PSMA and Lu177-DLL3 based therapies) may prove to be beneficial in PSMA-positive or DLL3-positive NEPC/DNPC, respectively, however most DNPC and NEPC tumours are negative for PSMA and only a subset of NEPC tumours express DLL3 [4,9,10,11,12]. This evidence concerns the gene DLL3 and neoplasm.